Business
Change of Registered Office
ValiRx Plc has announced a change to its registered office, relocating to 20 Wenlock Road, London, England, N1 7GU. This administrative update does not involve any financial figures or operational changes that would directly impact the company's stock share price. Disclaimer*
About this update from Valirx Plc
[{"type":"text","content":"\n\n \n31 March 2026\n \nValiRx PLC\n(\"ValiRx\" or the \"Company\")\n \nChange of Registered office\n \nLondon, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, announces that it has changed its registered office to 20 Wenlock Road, London, England, N1 7GU.\nThe Directors of the Company are responsible for the release of this announcement.\n \n*** ENDS ***\nEngage with the ValiRx management team directly by asking questions, watching video summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor hub here: https://valirx.com/s/cc8ef3\nFor more information, please contact:\n \n\n\n\n\nInvestor questions on this announcement\nWe encourage all investors to share questions\non this announcement via our investor hub\n\n\nhttps://valirx.com/link/PQbJDy\n \n \n\n\n\n\nValiRx plc\n \nDr Mark Eccleston, CEO\n \n \n\n\nTel: +44 115 784 0026\nwww.valirx.com\[email protected]\n \n \n\n\n\n\nCairn Financial Advisers LLP (Nominated Adviser)\n \nLiam Murray / Ludovico Lazzaretti\n \n\n\nTel: +44 (0) 20 7213 0880\n\n\n\n\nShard Capital Partners LLP (Sole Broker)\n \nDamon Heath\n \n\n\nTel: +44 (0) 20 7186 9000\n\n\n\n\nV Formation (Public Relations)\n \nLucy Wharton - Senior PR Executive\nSue Carr - Director\n \n\n\n+44 (0) 115 787 0206\nwww.vformation.biz\n \[email protected]\[email protected]\n\n\n\n\n \nSubscribe to our news alert service: https://valirx.com/s/f298d1\n \nNotes for Editors\nAbout ValiRx\nValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.\nValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.\nUsing its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.\nValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of...